<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226262</url>
  </required_header>
  <id_info>
    <org_study_id>CWX-03</org_study_id>
    <nct_id>NCT03226262</nct_id>
  </id_info>
  <brief_title>FFRangio Accuracy vs. Standard FFR</brief_title>
  <acronym>FAST-FFR</acronym>
  <official_title>FFRangio Accuracy vs. Standard FFR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CathWorks Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CathWorks Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, multi-center, single-arm, clinical trial designed to
      assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to
      Invasive FFR for diagnosing hemodynamically significant coronary stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of the dichotomously scored FFRangio measured index compared to invasive FFR</measure>
    <time_frame>1 hour</time_frame>
    <description>Sensitivity and specificity of the dichotomously scored FFRangio measured index per vessel as compared with invasively-derived FFR; Index ≤ 0.80 is scored &quot;positive&quot; while Index &gt; 0.8 is negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuously scored FFR (FFRangio and Invasive FFR).</measure>
    <time_frame>1 hour</time_frame>
    <description>Regression of FFRangio on continuous FFR, with slope, intercept and the correlation coefficient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy, Positive predictive value and negative predictive value per vessel and per lesion</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of the dichotomously scored FFRangio measured index per lesion as measured by the site.</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>1 hour</time_frame>
    <description>The ratio of produced FFRangio values from all FFRangio measurements that were started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability of FFRangio</measure>
    <time_frame>1 hour</time_frame>
    <description>A questionnaire will be completed by the user to assess how easy the system is for use and how intuitive it is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensiveness of the FFRangio User Manual in providing adequate instructions</measure>
    <time_frame>1 hour</time_frame>
    <description>A questionnaire will be completed to measure if the user understands the main parts of the software instructions after reading the Instructions for use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related Adverse and Serious Adverse Events</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related Adverse and Serious Adverse Events</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFRangio</intervention_name>
    <description>FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.
The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with stable angina, unstable angina or NSTEMI who are referred to coronary
        angiography and have an invasive FFR measurement with vasodilation in at least one coronary
        artery. Each subject will undergo both the standard invasive FFR and the investigational
        FFRangio.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, &gt;18 years of age.

          -  Patients with stable angina or unstable angina or NSTEMI, and in whom invasive FFR is
             being assessed in a non-culprit stenosis in at least one coronary artery.

          -  Subject is undergoing invasive FFR with Adenosine, ATP or Papaverine used as hyperemic
             stimulus.

          -  Provides written, informed consent (where required)

        Exclusion Criteria:

          -  Contraindication for FFR examination or administration of vasodilators.

          -  Subject is presenting with acute infarct (STEMI) OR has documented prior STEMI on same
             side (right/left).

          -  CTO in target vessel.

          -  Prior CABG, heart transplant or valve surgery, or prior TAVI/TAVR.

          -  Known LVEF ≤45%.

          -  Arteries supplying akinetic or severe hypokinetic territories if already known based
             on prior imaging.

          -  TIMI Grade 2 or lower at baseline.

          -  Target lesion involves Left Main (stenosis &gt;50%).

          -  PCI with stent in target vessel in past 12 months, or target vessel involves in-stent
             restenosis.

          -  Severe, diffuse disease defined as the presence of diffuse, serial gross luminal
             irregularities present in the majority of the coronary tree.

          -  Target coronary vessel is supplied by major collaterals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoa Ly</last_name>
      <phone>650-498-6279</phone>
      <email>hly@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Treena Williams</last_name>
      <phone>212-342-3485</phone>
      <email>taw2112@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay Kirtane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Haag</last_name>
      <phone>516-562-6790</phone>
      <email>Elizabeth.Haag@chsli.org</email>
    </contact>
    <investigator>
      <last_name>Allen Jeremias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Medenilla</last_name>
      <phone>215-614-0090</phone>
      <email>Elizabeth.Medenilla@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kolansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedwig Batjoens</last_name>
      <phone>32 53 72 41 68</phone>
      <email>hedwig.batjoens@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Stephan Fournier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigs Hospital CPH</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Loejmand</last_name>
      <phone>45 35450729</phone>
      <email>bettina.loejmand.mark@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Engstrøm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Rojansky</last_name>
      <phone>972 2 6555956</phone>
      <email>astrid@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Rami Joaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shlomit Halevi</last_name>
      <phone>972-3-9377107</phone>
      <email>shlomitha@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Abid Assali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HaSharon Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Greenberg, MD</last_name>
      <phone>972 3 9372251</phone>
      <email>Gabrigr@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Gabriel Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

